

Appendix 3: Clinical Full-Text Screening Checklist Reviewer: _____ Date: _____

Ref ID:			
Author:			
Publication Year:			
Did the study include:	Yes	Unclear	No
Did the study morade.	(Include)	(Include or exclude) ^a	(Exclude)
6) Adults (i.e., aged ≥ 18 years), being tested for PE			
(as per Table 2)			
7) The interventions of interest:			
Risk Stratification Strategies			
Wells or Geneva rules			
• PERC			
D-Dimer			
Biochemical or imaging studies			
Imaging			
CT-based studies			
MRI-based studies			
VQ-based studies			
PET-based studies			
Thoracic ultrasound			
8) The comparators of interest:			
Risk Stratification Strategies			
Composite reference standard			
Any alternative clinical decision rule or modified/tailored			
tool ± PERC ± D-dimer ± biochemical or imaging-based risk stratification			
No clinical rule (Gestalt)			
Imaging			
Composite reference standard			
CT-based studies			
MRI-based studies			
VQ-based studies			
PET-based studies			
Thoracic ultrasound			
The outcomes of interest:			
• DTA	_	_	_
Clinical utility			
Direct patient harms			
10) The study designs of interest:			
• SR			
• MA			
• HTA			
• RCT			
• NRS			
• CS			
Decision to include the study: ^b	Yes □		No □
· · · · · · · · · · · · · · · · · · ·			•



Ref ID:	
Author:	
Publication Year:	
Reason(s) for exclusion:	Inappropriate study population
	No intervention of interest
	No or inappropriate comparator
	No relevant outcomes
	Irrelevant study design
	Study description only
	Other:
CS = case series; CT = computed tomography; DTA = diagnostic test accuracy; HTA = health tectimaging; NRS = non-randomized study; PE = pulmonary embolism; PERC = Pulmonary Embolism; RCT = randomized controlled trial; SR = systematic review; VQ = ventilation-perfusion. a This will be discussed with a second reviewer. b If all items above are answered "yes" or "unclear," then the study will be included.	
Did the study report any data relevant to another research question (RQ)?	□ Yes: RQ# □ No